Bulls are likely to remain on the front foot in the upcoming sessions as well and any dip in the prices should be used to create fresh longs.

'Trade cautiously until unwinding cools off; Biocon among top 3 trading ideas'

For the rest of the week the range looks shifted towards 11,700-11,350 as of now.

Top stocks to bet on: ICICI Bank, Biocon, Rallis India can return 15-20% in near term

On the upside, the Nifty needs to sustain 10,800 for the uptrend to continue towards 11,100 and then possibly 11,350.

Building portfolio: Experts bet on 21 scrips to create wealth in coming years

Aashish Somaiyaa of Motilal Oswal Asset Management Company advised that one should avoid panic and remain invested.

Brokerages initiate buy on 11 stocks after COVID-led fall, expect 10-49% upside

Majority of experts started advising clients to accumulate quality stocks in a gradual manner with a long term view

Hot Stocks | Granules India, Dr Lal Path Lab, Navin Flourine are short-term buys

Positional Support for Nifty is seen at 8,900, and unless that is breached, the short-term trend of the market would be considered bullish only.

Analysts suggest these 15 quality mid-caps for 1-year investment horizon

Due to the COVID-19 pandemic, most large and mid-cap stocks have corrected significantly. They are expected to remain volatile unless the issue of coronavirus comes under control.

Coronavirus pain may linger; 10 stocks you can consider for your portfolio

Brokerages and analysts are of the view that the pain caused by COVID-19 may linger and the market is factoring in the hit on earnings and economic fallout from coronavirus outbreak.

Hot Stocks | Info Edge, Dr Lal Path Labs & Mahanagar Gas could return up to 12% in short term

After trading in a range of 12,270-12,180 odd levels during the five sessions, Nifty has seen a breakdown from the range, indicating the resumption of correction.

Bullish on 10 multi-cap stocks, brokerages expect 14-121% returns

'Better farm income coupled with the measures taken by the government and RBI will help improve demand conditions'

Nifty may head towards 12,350, 12,500; top 5 buying ideas which can return 12-17%

Breaking below 11,935, we expect profit booking towards 11,802. The low of 11,802 is now key pivotal support level for the market in the short term.

Diwali Picks: These 10 stocks likely to return 20-84% in Samvat 2076

BSE Smallcap index declined 9 percent, BSE Midcap index down 2 percent, while BSE largecap index added 10 percent in last one year.

Brokerages remain mixed on Dr Lal PathLabs Q2 show; Citi maintains buy rating

Brokerages remain mixed on Dr Lal PathLabs performance for the September quarter, with Morgan Stanley maintaining its underweight call on the stock, citing a miss on estimates and valuation issues.

Buy Dr Lal PathLabs, target Rs 1015: Aditya Agarwala

The stock may be bought in the range of Rs 925-930 for the target of Rs 985-1,015, keeping a stop loss below Rs 885.

These 3 midcaps may return 6-19% in next 3-4 weeks

Aditya Agarwala of Yes Securities says a sustained trade above 11,150 can extend the current upmove to 11,185-11,245 levels

UBS handpicks 10 midcaps that could return up to 62% in the next 1 year

UBS said the relative valuation of small and midcaps suggest that optimism may be priced but not the uncertainties, despite the recent corrections.

Buy, Sell, Hold: 7 stocks are tracking by analysts on February 9

CLSA has retained its Underperform rating on Cadila with reduced target price at Rs 440 from Rs 480 per share earlier following cut in FY19-20 margin estimate by 100 bps & earnings by 5-7 percent.

Budget 2018: Not sure where to invest post Budget? Top 20 winning stocks to buy

“On the overall basis, long-term capital gains tax doesn’t look dampening and revenue growth assumptions are looking realistic. Investors should focus on sectors/stocks having agri or rural theme. Escorts, Ashok Leyland, M&M, PI Inds and UPL will be positive,” Hemang Jani, Head Equity Sales & Advisory, Sharekhan told Moneycontrol.

Dr Lal PathLabs may test Rs 1050: Prakash Gaba

Prakash Gaba of prakashgaba.com is of the view that Dr Lal PathLabs may test Rs 1050.

Prefer Apollo Hospitals: Gaurang Shah

Gaurang Shah of Geojit Financial Services is of the view that one may prefer Apollo Hospitals.

5 stocks where brokerages retained buy post Q2 results can give up to 30% upside

The pharma companies have posted mix earnings in the quarter ended September 2017 on the back pricing pressure and increased competition.

Buy, Sell, Hold: 5 stocks being tracked by analysts today

Tata Motors, Dr Lal and Page Industries, among others, are on the radar of investors on Friday.

Buy Motilal Oswal, Hindustan Copper, EIL, DHFL, Dr Lal PathLabs; sell Escorts: Ashwani Gujral

Ashwani Gujral of ashwanigujral.com is of the view that one can buy Motilal Oswal, Hindustan Copper, Engineers India, DHFL and Dr Lal PathLabs and advises selling Escorts.

Here are SP Tulsian's top trading ideas

In an interview to CNBC-TV18's Latha Venkatesh and Anuj Singhal, SP Tulsian of sptulsian.com shared his views and outlook on the fundamentals of the market and specific stocks.

Buy, Sell, Hold: Analysts are tracking these 4 stocks today

Tata Steel and Welspun India, among others, are on the radar of investors on Tuesday.